NASDAQ:MGX Metagenomi Q4 2024 Earnings Results & Report $0.82 +0.12 (+17.14%) As of 12:37 PM Eastern This is a fair market value price provided by Massive. Learn more. Metagenomi missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 17, 2025. The company reported EPS of -$0.63 versus the -$0.62 consensus estimate, while revenue of $9.61 million fell short of the $13.18 million estimate by $3.57 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 17, 2025TimeBefore Market OpensConference Call9:30 AM ET Metagenomi EPS ResultsActual EPS-$0.63Consensus EPS -$0.62Beat/MissMissed by -$0.01One Year Ago EPS-$20.05EPS Beat Rate3 of last 8 quartersMetagenomi Revenue ResultsActual Revenue$9.61 millionExpected Revenue$13.18 millionBeat/MissMissed by -$3.57 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Metagenomi Q4 2024 Earnings FAQ Did Metagenomi beat earnings estimates for Q4 2024? Metagenomi (NASDAQ:MGX) reported earnings of -$0.63 per share for Q4 2024, missing the consensus estimate of -$0.62. The report was announced on Monday, March 17, 2025. What was Metagenomi's revenue for Q4 2024? Metagenomi reported revenue of $9.61 million for Q4 2024, against a consensus estimate of $13.18 million. Metagenomi Earnings HeadlinesMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London4 hours ago | globenewswire.comMetagenomi Gets Investigational Approval for Hemophilia TreatmentNovember 10 at 7:26 PM | marketscreener.comMThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)Metagenomi Therapeutics: Q3 earnings snapshotNovember 10 at 7:26 PM | msn.comMetagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial ResultsNovember 10 at 4:05 PM | globenewswire.comMetagenomi (MGX) Expected to Post Earnings on TuesdayNovember 9 at 1:40 AM | americanbankingnews.comSee More Metagenomi Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email. Email Address About MetagenomiMetagenomi (NASDAQ:MGX) is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools. Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction. Its research activities have included the discovery of novel nucleases and other genome-editing components, as well as the advancement of potential therapeutic programs in areas such as metabolic and liver-related disorders. Founded in 2018, Metagenomi is based in Emeryville, California. The company’s work is primarily focused on research and development, with its products and programs intended for potential use in human medicine rather than commercial sale. Metagenomi became a publicly traded company on the Nasdaq under the symbol MGX in 2024.View Metagenomi ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions3 Stocks Wall Street Likes More Than the Market DoesD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
